MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma

Qiang Wang, Dongyu Zhao, Miao Xian, Zhuo Wang, Enguang Bi, Pan Su, Jianfei Qian, Xingzhe Ma, Maojie Yang, Lintao Liu, Youli Zu, Sai Ravi Pingali, Kaifu Chen, Zhen Cai, Qing Yi

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Multiple myeloma (MM) remains largely incurable despite significant advances in biotherapy and chemotherapy. The development of drug resistance is a major problem in MM management. Macrophage migration inhibitory factor (MIF) expression was significantly higher in purified MM cells from relapsed patients than those with sustained response, and MM patients with high MIF had significantly shorter progression-free survival (PFS) and overall survival (OS). MM cell lines also express high levels of MIF, and knocking out MIF made them more sensitive to proteasome inhibitor (PI)-induced apoptosis not observed with other chemotherapy drugs. Mechanistic studies showed that MIF protects MM cells from PI-induced apoptosis by maintaining mitochondrial function via suppression of superoxide production in response to PIs. Specifically, MIF, in the form of a homotrimer, acts as a chaperone for superoxide dismutase 1 (SOD1) to suppress PI-induced SOD1 misfolding and to maintain SOD1 activity. MIF inhibitor 4-iodo-6-phenylpyrimidine and homotrimer disrupter ebselen, which do not kill MM cells, enhanced PI-induced SOD1 misfolding and loss of function, resulting in significantly more cell death in both cell lines and primary MM cells. More importantly, inhibiting MIF activity in vivo displayed synergistic antitumor activity with PIs and resensitized PI-resistant MM cells to treatment. In support of these findings, gene-profiling data showed a significantly negative correlation between MIF and SOD1 expression and response to PI treatment in patients with MM. This study shows that MIF plays a crucial role in MM sensitivity to PIs and suggests that targeting MIF may be a promising strategy to (re)sensitize MM to the treatment.

Original languageEnglish (US)
Pages (from-to)2557-2573
Number of pages17
Issue number22
Early online dateJun 24 2020
StatePublished - Nov 26 2020

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma'. Together they form a unique fingerprint.

Cite this